PHOTOCURE
PHO
ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE
Photocure ASA: Update on Regulatory Classification for OAY Equipment
Oslo, Norway, April 13, 2026 - Photocure ASA (OSE: PHO) today announced that the U.S. Food and Drug Administration (FDA) has communicated to Photocure that it plans to issue a proposed order to reclassify diagnostic endoscopic light source systems (FDA Product Code OAY) under its own initiative per Section 513(f)(3) of the Federal Food, Drug, and Cosmetic Act.
This information was shared with Photocure as part of its ongoing dialogue with the FDA, following the Reclassification Petition submitted by Karl Storz SE & Co. KG and addressed in Photocure's press release of 28 March 2026. Consistent with FDA's response to the Reclassification Petition, which did not preclude the agency from reclassifying on its own initiative, and subject to internal processes, FDA intends on issuing a proposed order to reclassify FDA Product Code OAY in the second half of 2026. Any potential reclassification will proceed through the FDA's established processes, with final determinations made by the agency.
For further information, please contact:
Dan Schneider President and CEO Photocure ASA Email:ds@photocure.com
Erik Dahl CFO Photocure ASA Tel: +47 45055000 Email:ed@photocure.com
Priyam Shah Vice President Investor Relations Tel: +17176815072 Email:priyam.shah@photocure.com
Media and IR enquiries:
Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email:geir.bjorlo@corpcom.no
About Photocure Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com/news.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Tolv Hillestad, Photocure ASA, on 13 April 2026 at 08:30 CEST.